rs2414096 — CYP19A1 CYP19A1 intron 4 polymorphism

CYP19A1 Intron 4 Variant — An Aromatase Regulator With Population-Dependent Effects on Androgen Balance

Aromatase¹¹ Aromatase
the enzyme encoded by CYP19A1 that catalyzes the final and rate-limiting step of estrogen biosynthesis, converting androgens such as androstenedione and testosterone to estrogens is expressed in the ovaries, adipose tissue, bone, brain, and adrenal glands. Because it is the only enzyme capable of estrogen synthesis in vertebrates, even small changes in its expression can meaningfully shift the androgen–estrogen balance. The rs2414096 variant lies in intron 4 of CYP19A1 on chromosome 15 and does not alter the protein sequence, but several lines of evidence suggest it may influence aromatase expression levels or transcript regulation, with downstream effects on androgen-to-estrogen conversion.

The Mechanism

As an intronic variant, rs2414096 does not directly alter aromatase enzyme structure. Instead, it may act through effects on splicing efficiency, mRNA stability, or linkage disequilibrium with nearby regulatory elements. CYP19A1 is a complex locus with multiple tissue-specific promoters controlling aromatase expression in different organs; intronic variants can modulate these promoter activities in tissue-specific ways. The variant is located on chromosome 15 at position 51,237,582 (GRCh38), within intron 4, and CYP19A1 itself is transcribed from the minus strand²² CYP19A1 itself is transcribed from the minus strand. The GRCh38 reference allele (G) — corresponding to a C on the coding strand — appears to be the allele associated with lower aromatase activity based on multiple functional and association studies.

The Evidence

The primary evidence base consists of association studies across multiple populations, two meta-analyses, and a study linking this variant to direct hormone-level differences.

A 2021 meta-analysis of seven studies (1,414 PCOS cases, 1,276 controls) by Sharma et al.³³ A 2021 meta-analysis of seven studies (1,414 PCOS cases, 1,276 controls) by Sharma et al.
CYP19 gene rs2414096 variant and differential genetic risk of polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol 2021 found that the GG dominant model (GG+GA vs AA) was significantly associated with PCOS risk (OR=1.60, 95% CI 1.10–2.31, p=0.01), with the overall A-allele effect estimate of OR=0.74 (95% CI 0.62–0.88, p=0.0008), indicating the A allele is protective. The association was statistically significant in non-Indian populations but not Indian subpopulations, where genetic diversity is greater.

However, a larger 2022 meta-analysis by Xing et al. of 26 studies (4,860 PCOS cases, 4,043 controls)⁴⁴ a larger 2022 meta-analysis by Xing et al. of 26 studies (4,860 PCOS cases, 4,043 controls)
The Association of CYP17A1, CYP19A1, and SHBG Gene Polymorphisms in Polycystic Ovary Syndrome Susceptibility. Front Physiol 2022 found no statistically significant overall association (OR=0.87, p=0.578) with extreme heterogeneity (I²=95.9%), underscoring that this variant's effects are genuinely population-dependent rather than universal.

Genotype-specific hormone data strengthen the mechanistic case. An analysis of 394 Kashmiri PCOS patients and 306 controls found that the GG genotype was associated with significantly elevated DHEAS, androstenedione, testosterone, and free androgen index⁵⁵ An analysis of 394 Kashmiri PCOS patients and 306 controls found that the GG genotype was associated with significantly elevated DHEAS, androstenedione, testosterone, and free androgen index
Ashraf et al. 2021. Impact of rs2414096 polymorphism of CYP19 gene on susceptibility of polycystic ovary syndrome and hyperandrogenism in Kashmiri women. Sci Rep 2021 (all comparisons p<0.05), supporting the hypothesis that the G allele reduces aromatase-driven androgen conversion. Similarly, a South Indian study of 150 PCOS patients found GG more prevalent among cases, with elevated LH/FSH ratios in GG carriers, and concluded that GG may exhibit reduced aromatase activity with subsequent hyperandrogenism⁶⁶ South Indian study of 150 PCOS patients found GG more prevalent among cases, with elevated LH/FSH ratios in GG carriers, and concluded that GG may exhibit reduced aromatase activity with subsequent hyperandrogenism
Hegde et al. 2023. Delineating the role of single-nucleotide polymorphism of CYP19 gene on aromatase activity in South Indian women with PCOS. J Genet Eng Biotechnol 2023.

On the question of circulating hormones, the SWAN study of 1,538 multiethnic midlife women found that Caucasian women with the AA genotype had markedly lower SHBG levels after adjusting for age and BMI⁷⁷ the SWAN study of 1,538 multiethnic midlife women found that Caucasian women with the AA genotype had markedly lower SHBG levels after adjusting for age and BMI
Sowers et al. 2006. Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. Am J Med 2006. Lower SHBG increases free testosterone bioavailability, which may appear directionally contradictory to the PCOS data above — it suggests AA carriers have higher free androgen exposure despite a proposed protective effect on PCOS. This likely reflects tissue-specific or context-specific aromatase regulation: ovarian aromatase activity and circulating SHBG regulation are influenced by different promoters and feedback mechanisms. Context matters, and a single intronic variant almost certainly does not have a unidirectional effect across all tissues simultaneously.

Practical Actions

For women with PCOS features — irregular cycles, hirsutism, elevated androgens, or anovulatory infertility — the GG genotype adds a modest piece of evidence supporting impaired androgen-to-estrogen conversion in the ovary. This reinforces evaluation of androgen levels alongside this genotype, and consideration of aromatase-relevant interventions when clinically appropriate. Letrozole (an aromatase inhibitor paradoxically used to stimulate ovulation in PCOS by briefly lowering estrogen feedback, prompting FSH surge) is the standard-of-care first-line ovulation induction agent in PCOS; whether this genotype modifies letrozole response is an open question with no prospective pharmacogenomic data yet.

The heterogeneous evidence means this variant should be interpreted in the context of clinical findings, not used as a standalone diagnostic marker.

Interactions

Rs2414096 is part of the CYP19A1 locus alongside rs700518 (Val80, synonymous variant affecting aromatase expression and AI side-effect risk), rs700519 (Arg264Cys, coding variant with increased catalytic activity in vitro), and rs1062033 (intronic regulatory variant with CEBPβ-mediated transcriptional effect on aromatase in bone). These variants form haplotypes and may have compounded effects on total aromatase expression and activity — their combined influence on androgen–estrogen balance in reproductive tissues, bone, and adipose tissue is likely greater than any individual variant's effect alone. Women carrying risk genotypes across multiple CYP19A1 loci may have a broader pattern of altered estrogen synthesis worth evaluating with comprehensive hormone panels.